国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
Business
Home / Business / Companies

AstraZeneca confident to invest more in China

By Liu Zhihua | chinadaily.com.cn | Updated: 2022-11-16 15:57
Share
Share - WeChat
Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken on May 21, 2021. [Photo/Agencies]

China's continued pursuit of high-quality economic development will foster sustainable growth of the Chinese economy, making biopharmaceutical giant AstraZeneca more confident in investing more in China, according to a senior executive of the company.

"As we look at China's role on the global stage, and in particular through this year's China International Import Expo and its opening ceremony, we have gained strong confidence in the Chinese economy," said Michael Lai, general manager of AstraZeneca China, in a recent exclusive interview with China Daily.

COVID-19 has had a worldwide impact, creating short term fluctuations. But when looking at the longer-term economic outlook of China, it's very important for AstraZeneca to continue to take China as an increasingly important global supply base, according to him.

The company has announced earlier this year its intentions to further invest in its manufacturing facilities in China, including Wuxi and Taizhou supply bases in Jiangsu province. The company is also establishing a new supply base in Qingdao, Shandong province.

According to Lai, the Qingdao investment program is part of one of the core strategies of AstraZeneca in the respiratory disease sector over the next 10 or more years, as the Qingdao supply facility will be an important base for global manufacturing, serving not just the Chinese market, but also the rest of the world.

Lai said as China pushes for high-level opening-up, the company sees a strong environment of collaboration and cooperation between global companies working in China, as well as an environment that allows Chinese companies to be able to reach out to the world.

He is also impressed by Chinese innovation.

"We are partnering with innovative Chinese companies, like Wuxi Biologics, to further expand our partnership in COVID-19 vaccines, as well neutralizing anti-bodies," he said.

"The Chinese pharmaceutical industry is at a growth phase in terms of world-class innovation. We are very excited to see a new generation of innovative biotech companies in China," he added. 

liuzhihua@chinadaily.com.cn

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
乌拉特中旗| 平顶山市| 棋牌| 涞源县| 班玛县| 若尔盖县| 四川省| 内黄县| 双鸭山市| 庆阳市| 郸城县| 正镶白旗| 六盘水市| 莲花县| 会宁县| 张家界市| 娄烦县| 团风县| 香港 | 宣恩县| 定远县| 大姚县| 旌德县| 冕宁县| 游戏| 东海县| 望城县| 清涧县| 寿阳县| 永新县| 揭东县| 亚东县| 山阴县| 建昌县| 明溪县| 济源市| 汨罗市| 榕江县| 丁青县| 格尔木市| 高雄市|